Literature DB >> 16314192

Effects of two common polymorphisms of peroxisome proliferator-activated receptor-gamma gene on metabolic syndrome.

Eun Jung Rhee1, Ki Won Oh, Won Young Lee, Se Yeon Kim, Eun Sook Oh, Ki Hyun Baek, Moo Il Kang, Sun Woo Kim.   

Abstract

BACKGROUND: Peroxisome proliferator-activated receptor (PPAR)gamma is involved mainly in adipocyte differentiation and has been suggested to play an important role in the pathogenesis of insulin resistance and atherosclerosis. We investigated the frequencies of two common polymorphisms of PPARgamma gene, exon 6 C-->T substitution and exon B Pro12Ala in healthy subjects and analyzed the correlations between the different genotypes and insulin resistance, metabolic syndrome and cardiovascular risk factors.
METHODS: Anthropometric measurements, fasting glucose, insulin and lipid profiles were measured in 253 Korean females. Homeostatic model assessments and quantitative insulin sensitivity check indices were calculated. Metabolic syndrome was diagnosed according to the NCEP-ATP III guidelines and the Western Pacific Region of WHO for obesity criteria for waist circumference. Polymerase chain reaction (PCR)-restriction fragment-length polymorphism and real-time PCR were performed for genotyping of the DNAs.
RESULTS: For C161T polymorphism, allele frequencies were 0.804 and 0.196 for T allele, and 0.947 for proline and 0.053 for alanine. There was no Ala12Ala homozygote in the population. No differences were seen in the mean values of age, body mass index (BMI), blood pressure, fasting blood glucose level, fasting insulin levels, HOMA and QUICKI among different genotypes when analyzed as a whole, except that subjects with Pro12Ala had significantly higher body weight than those with Pro12Pro genotype. However, mean BMI, percent body fat and weight showed significant differences between genotypes in younger age group (< or =50 years). Although overall prevalence of metabolic syndrome had no association with the genotypes, the prevalence of decreased high-density lipoprotein cholesterol component was lower in those with the T allele than in those with the CC genotype. There was no association of the genotypes with glucose tolerance status. When the subjects were divided into four groups according to the combination of the genetic alleles of the two polymorphisms, subjects having Pro12Ala and T allele, simultaneously, showed significantly higher mean weight than those without Ala allele. Pro12Ala polymorphism seems to affect body weight, similar to the previous studies, and the effect was potentiated with the presence of T allele of C161T polymorphism.
CONCLUSIONS: Although either polymorphism failed to show significant association with insulin resistance, the fact that the prevalence of decreased HDL-C was lower in those with the T allele of C161T polymorphism suggests that this polymorphism might have a protective effect on atherosclerotic lipid profiles, which needs further investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16314192     DOI: 10.1016/j.arcmed.2005.04.008

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  27 in total

1.  APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome.

Authors:  Michael Miller; Jeffrey Rhyne; Hegang Chen; Valerie Beach; Richard Ericson; Kalpana Luthra; Manjari Dwivedi; Anoop Misra
Journal:  Arch Med Res       Date:  2007-03-26       Impact factor: 2.235

Review 2.  HDL cholesterol and bone mineral density: is there a genetic link?

Authors:  Cheryl L Ackert-Bicknell
Journal:  Bone       Date:  2012-02       Impact factor: 4.398

3.  Effect of the PPARγ C161T gene variant on serum lipids in ischemic stroke patients with and without type 2 diabetes mellitus.

Authors:  Khouloud Chehaibi; Samir Nouira; Kacem Mahdouani; Sonia Hamdi; Mustapha Rouis; Mohamed Naceur Slimane
Journal:  J Mol Neurosci       Date:  2014-05-21       Impact factor: 3.444

Review 4.  PPARgamma in human and mouse physiology.

Authors:  Sami Heikkinen; Johan Auwerx; Carmen A Argmann
Journal:  Biochim Biophys Acta       Date:  2007-03-27

5.  Associations between C1431T and Pro12Ala variants of PPARγ gene and their haplotypes with susceptibility to metabolic syndrome in an Iranian population.

Authors:  Hassan Rooki; Monir-sadat Haerian; Pedram Azimzadeh; Reza Mirhafez; Mahmoud Ebrahimi; Gordon Ferns; Majid Ghayour-Mobarhan; Mohammad-Reza Zali
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

6.  Association analysis of peroxisome proliferator-activated receptors gamma gene polymorphisms with asprin hypersensitivity in asthmatics.

Authors:  Sun-Hee Oh; Se-Min Park; Jong-Sook Park; An-Soo Jang; Yong-Mok Lee; Soo-Taek Uh; Young Hoon Kim; In-Seon Choi; Mi-Kyeong Kim; Byeong Lae Park; Hyoung-Doo Shin; Choon-Sik Park
Journal:  Allergy Asthma Immunol Res       Date:  2009-09-25       Impact factor: 5.764

7.  Association and interaction of PPAR-complex gene variants with latent traits of left ventricular diastolic function.

Authors:  Jyh-Ming Jimmy Juang; Lisa de Las Fuentes; Alan D Waggoner; C Charles Gu; Víctor G Dávila-Román
Journal:  BMC Med Genet       Date:  2010-04-28       Impact factor: 2.103

8.  PPARG: Gene Expression Regulation and Next-Generation Sequencing for Unsolved Issues.

Authors:  Valerio Costa; Maria Assunta Gallo; Francesca Letizia; Marianna Aprile; Amelia Casamassimi; Alfredo Ciccodicola
Journal:  PPAR Res       Date:  2010-09-08       Impact factor: 4.964

9.  The association between genetic variants of RUNX2, ADIPOQ and vertebral fracture in Korean postmenopausal women.

Authors:  Kyong-Chol Kim; Hyejin Chun; ChaoQiang Lai; Laurence D Parnell; Yangsoo Jang; Jongho Lee; Jose M Ordovas
Journal:  J Bone Miner Metab       Date:  2014-02-26       Impact factor: 2.626

10.  Two novel SNPs in the coding region of the bovine PRDM16 gene and its associations with growth traits.

Authors:  J Wang; Z J Li; X Y Lan; L S Hua; Y T Huai; Y Z Huang; L Ma; M Zhao; Y J Jing; H Chen; J Q Wang
Journal:  Mol Biol Rep       Date:  2010-01       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.